Erlotinib Withdrawn Phase 2 Trials for Solid Tumors and Hematologic Malignancy / Carcinoma NOS / NSCLC (Non-small Cell Lung Carcinoma) / Lung Cancer Non-Small Cell Cancer (NSCLC) Treatment

IndicationsStatusPurposePhase
WithdrawnTreatment2
clinicaltrials.gov IdentifierTitleDrugs
NCT02355431Itacitinib in Combination With Erlotinib in Non Small Cell Lung Cancer Patients With Epidermal Growth Factor Receptor (EGFR) Activating Mutations